Home

Download

Statistics

Landscape

Help

Contact

	Dataset summary
	Drug summary
	Umap of single cell types and conditions (resistant and sensitive)
	Comparison of cell composition between the resistant and sensitive groups (This dataset does not contain this module)
	Comparison of intra-tumor heterogeneity (ITH) and epithelial-mesenchymal transition (EMT) scores of malignant cells between the resistant and sensitive groups
	Difference of cell-cell interactions between the resistant and sensitive groups (This dataset does not contain this module)
	Differentially expressed genes (DEGs) between the resistant and sensitive groups for each cell type
	Mechanism analysis of drug resistance-related DEGs for each cell type in the pre-treatment samples (This dataset does not contain this module)
	Mechanism analysis of drug resistance-related DEGs for each cell type in the post-treatment samples (This dataset does not contain this module)
	Mechanism analysis of drug resistance-related DEGs for each cell type in one patient or cell lines
	MicroRNAs (miRNAs) regulating drug resistance-related DEGs for Malignant cells
	Motifs and transcription factors (TFs) regulating drug resistance-related DEGs for each cell type
•	Differentially expressed genes act as transcription factors

Dataset: GSE164897_VemTra

Dataset summary for GSE164897_VemTra

Datast information	Dataset	GSE164897_VemTra
	PMID	34591417
	Raw data ID/link	PRJNA692421
	Organism	Homo sapiens
	Source	A375 cell line
	Tissue	Cell line
	Cancer type level1	Melanoma
	Cancer type level2	B+E2:E57RAFV600E-mutant melanoma
	Regimen	vemurafenib + trametinib
	Drug type	Targeted therapy
	Sample size	resistant 1, sensitive 1
	Cell number	15718
	Extract protocol	10x genomics
	Data processing	CellRanger
	Public date	Public on Jan 16, 2021
	Description	This dataset has 1 cell line with a sensitive pre-treatment sample and a resistant post-treatment sample.

Top

Drug summary for GSE164897_VemTra

Drug name	DrugBank ID	Drug type	Targets name	Targets uniprot ID
"Vemurafenib"	DB08881	small molecule	BRAF	P15056
"Trametinib"	DB08911	small molecule	MAP2K1; MAP2K2	Q02750; P36507

Top

Umap of single cell types and conditions (resistant and sensitive)

Umap of cell types and conditions (resistant and sensitive). If this dataset has both pre-treatment and post-treatment samples, the cell types were annotated together. If this dataset is a cell line dataset, the UMAP of cell clusters and the cell ratio of drug-resistant and sensitive groups within each cluster will also be shown. (If the image exists, the user can click on it to enlarge it in a new window.)

Umap of cell types	Umap of conditions
Umap of cell clusters	Cell ratio of drug-resistant and sensitive groups within each cluster

Top

Comparison of cell composition between the resistant and sensitive groups

In the pre-treatment samples, the cell composition of the resistant and sensitive groups were compared.
* represents significant difference. (If the image exists, the user can click on it to enlarge it in a new window.)

In the post-treatment samples, the cell composition of the resistant and sensitive groups were compared.
* represents significant difference. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Comparison of ITH and EMT scores of malignant cells between the resistant and sensitive groups

Comparison of ITH (intra-tumoral heterogeneity) and EMT (epithelial-mesenchymal transition) scores of malignant cells between the resistant and sensitive groups. ITH represents intratumoral heterogeneity, EMT represents epithelial mesenchymal transition, pre represents pre-treatment, post represents post-treatment, post2 represents longer post-treatment. (If the image exists, the user can click on it to enlarge it in a new window.)

Comparison of ITH scores

Comparison of EMT scores

Top

Difference of cell-cell interactions between the resistant and sensitive groups

In the pre-treatment samples, the difference in cell-cell interactions between the resistant and sensitive groups was compared. The numbers indicate the count of cell-cell interactions that were either higher or lower in the resistant group compared to the sensitive group. The dot plots of significant ligand-receptor pairs in the resistant group and sensitive group are subsequently displayed. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

In the post-treatment samples, the difference in cell-cell interactions between the resistant and sensitive groups was compared. The numbers indicate the count of cell-cell interactions that were either higher or lower in the resistant group compared to the sensitive group. The dot plots of significant ligand-receptor pairs in the resistant group and sensitive group are subsequently displayed. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

This dataset only has one patient or is a cell line dataset, the resistant sample is the post-treatment sample and the sensitive sample is the pre-treatment sample. The difference in cell-cell interactions between the resistant and sensitive groups was compared. The numbers indicate the count of cell-cell interactions that were either higher or lower in the resistant group compared to the sensitive group. The dot plots of significant ligand-receptor pairs in the resistant group and sensitive group are subsequently displayed. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Top

Differentially expressed genes (DEGs) between the resistant and sensitive groups for each cell type

In the pre-treatment samples, the differentially expressed genes (|avg_log2FC|>0.25 & p_val_adj<0.05) between the resistant and sensitive groups for each cell type.

In the post-treatment samples, the differentially expressed genes (|avg_log2FC|>0.25 & p_val_adj<0.05) between the resistant and sensitive groups for each cell type.

This dataset only has one patient or is a cell line dataset, the resistant sample is the post-treatment sample and the sensitive sample is the pre-treatment sample. The following are differentially expressed genes (|avg_log2FC|>0.25 & p_val_adj<0.05) between the resistant and sensitive groups for each cell type.

Gene symbol	Gene id	avg_log2FC	p_val	p_val_adj	pct.1	pct.2	Cell type	Timepoint
EIF2S3	ENSG00000130741	0.418335	0.00e+00	0.00e+00	0.514	0.427	Malignant cells	NA
DSCR8	ENSG00000198054	0.418072	0.00e+00	0.00e+00	0.304	0.083	Malignant cells	NA
RAB5B	ENSG00000111540	0.415599	0.00e+00	0.00e+00	0.305	0.081	Malignant cells	NA
SPTSSA	ENSG00000165389	0.414334	0.00e+00	0.00e+00	0.36	0.193	Malignant cells	NA
NDUFS4	ENSG00000164258	0.412343	0.00e+00	0.00e+00	0.54	0.448	Malignant cells	NA
PTP4A2	ENSG00000184007	0.4101	0.00e+00	0.00e+00	0.389	0.203	Malignant cells	NA
ADAR	ENSG00000160710	0.408987	0.00e+00	0.00e+00	0.372	0.166	Malignant cells	NA
TMBIM4	ENSG00000155957	0.408318	0.00e+00	0.00e+00	0.36	0.191	Malignant cells	NA
ACP1	ENSG00000143727	0.407581	0.00e+00	0.00e+00	0.596	0.546	Malignant cells	NA
PNISR	ENSG00000132424	0.406413	0.00e+00	0.00e+00	0.43	0.269	Malignant cells	NA
NORAD	ENSG00000260032	0.406307	0.00e+00	0.00e+00	0.409	0.229	Malignant cells	NA
DYNLRB1	ENSG00000125971	0.40588	0.00e+00	0.00e+00	0.623	0.569	Malignant cells	NA
FSTL1	ENSG00000163430	0.40567	0.00e+00	0.00e+00	0.253	0.027	Malignant cells	NA
RPL15	ENSG00000174748	0.403718	0.00e+00	0.00e+00	1	1	Malignant cells	NA
PRRC2C	ENSG00000117523	0.403179	0.00e+00	0.00e+00	0.534	0.436	Malignant cells	NA
RPL26	ENSG00000161970	0.40222	0.00e+00	0.00e+00	1	1	Malignant cells	NA
RHOQ	ENSG00000119729	0.402095	0.00e+00	0.00e+00	0.262	0.045	Malignant cells	NA
EIF3H	ENSG00000147677	0.401255	0.00e+00	0.00e+00	0.841	0.799	Malignant cells	NA
STC1	ENSG00000159167	0.398453	0.00e+00	0.00e+00	0.261	0.08	Malignant cells	NA
WDR83OS	ENSG00000105583	0.396242	0.00e+00	0.00e+00	0.875	0.852	Malignant cells	NA
MT-ND2	ENSG00000198763	0.396163	0.00e+00	0.00e+00	1	1	Malignant cells	NA
TNS3	ENSG00000136205	0.396007	0.00e+00	0.00e+00	0.259	0.055	Malignant cells	NA
CTNNA1	ENSG00000044115	0.395176	0.00e+00	0.00e+00	0.411	0.247	Malignant cells	NA
IGFBP3	ENSG00000146674	0.392022	0.00e+00	0.00e+00	0.254	0.147	Malignant cells	NA
CAPZA1	ENSG00000116489	0.388555	0.00e+00	0.00e+00	0.395	0.241	Malignant cells	NA
CRIPT	ENSG00000119878	0.386725	0.00e+00	0.00e+00	0.455	0.323	Malignant cells	NA
GTF2H5	ENSG00000272047	0.386665	0.00e+00	0.00e+00	0.386	0.229	Malignant cells	NA
NONO	ENSG00000147140	0.383555	0.00e+00	0.00e+00	0.535	0.443	Malignant cells	NA
ALDH1A3	ENSG00000184254	0.376808	0.00e+00	0.00e+00	0.338	0.193	Malignant cells	NA
PFN2	ENSG00000070087	0.374205	0.00e+00	0.00e+00	0.439	0.308	Malignant cells	NA
BBX	ENSG00000114439	0.374114	0.00e+00	0.00e+00	0.444	0.308	Malignant cells	NA
SERINC3	ENSG00000132824	0.372399	0.00e+00	0.00e+00	0.407	0.261	Malignant cells	NA
MORN2	ENSG00000188010	0.372293	0.00e+00	0.00e+00	0.342	0.163	Malignant cells	NA
RPL36A	ENSG00000241343	0.371318	0.00e+00	0.00e+00	0.997	0.995	Malignant cells	NA
AHCYL1	ENSG00000168710	0.370166	0.00e+00	0.00e+00	0.348	0.184	Malignant cells	NA
RPL5	ENSG00000122406	0.366774	0.00e+00	0.00e+00	1	0.999	Malignant cells	NA
ABCC3	ENSG00000108846	0.366302	0.00e+00	0.00e+00	0.254	0.057	Malignant cells	NA
ATP5PD	ENSG00000167863	0.366042	0.00e+00	0.00e+00	0.692	0.692	Malignant cells	NA
CELF1	ENSG00000149187	0.36483	0.00e+00	0.00e+00	0.379	0.222	Malignant cells	NA
KANK2	ENSG00000197256	0.363988	0.00e+00	0.00e+00	0.292	0.107	Malignant cells	NA
GLG1	ENSG00000090863	0.363055	0.00e+00	0.00e+00	0.337	0.164	Malignant cells	NA
MRPS33	ENSG00000090263	0.3624	0.00e+00	0.00e+00	0.551	0.487	Malignant cells	NA
GANAB	ENSG00000089597	0.360664	0.00e+00	0.00e+00	0.412	0.274	Malignant cells	NA
TCAF1	ENSG00000198420	0.359723	0.00e+00	0.00e+00	0.282	0.084	Malignant cells	NA
ACLY	ENSG00000131473	0.355988	0.00e+00	0.00e+00	0.306	0.137	Malignant cells	NA
OSTC	ENSG00000198856	0.355861	0.00e+00	0.00e+00	0.452	0.356	Malignant cells	NA
GTF2I	ENSG00000263001	0.355477	0.00e+00	0.00e+00	0.357	0.196	Malignant cells	NA
H1-2	ENSG00000187837	0.355058	0.00e+00	0.00e+00	0.341	0.196	Malignant cells	NA
EIF4A2	ENSG00000156976	0.354108	0.00e+00	0.00e+00	0.456	0.335	Malignant cells	NA
CKAP4	ENSG00000136026	0.35381	0.00e+00	0.00e+00	0.359	0.205	Malignant cells	NA

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30

Top

Mechanism analysis of drug resistance-related DEGs for each cell type in the pre-treatment samples

Enrichment results for 5 known drug-resistant mechanisms in malignant cells and 1 known mechanism in TME cells.The "Signature" column represents the differentially expressed genes (DEGs) used for enrichment. The "Geneset" column represents the genes included in this mechanism. The "Overlap" column represents the number of genes in the "Geneset" that are enriched in the "Signature". The "Enriched Genes" column represents the genes in the "Geneset" that are enriched in the "Signature". (If the image exists, the user can click on it to enlarge it in a new window.)

Hallmark, KEGG and GOBP enrichment results for up-regulated genes in resistant group of pre-treatment samples. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Hallmark, KEGG and GOBP enrichment results for down-regulated genes in resistant group of pre-treatment samples. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window.Complete files can be downloaded from the download section.)

Top

Mechanism analysis of drug resistance-related DEGs for each cell type in the post-treatment samples

Enrichment results for 5 known drug resistance mechanisms in malignant cells and 1 known mechanism in TME cells.The "Signature" column represents the differentially expressed genes (DEGs) used for enrichment. The "Geneset" column represents the genes included in this mechanism. The "Overlap" column represents the number of genes in the "Geneset" that are enriched in the "Signature". The "Enriched Genes" column represents the genes in the "Geneset" that are enriched in the "Signature". (If the image exists, the user can click on it to enlarge it in a new window.)

Hallmark, KEGG and GOBP enrichment results for up-regulated genes in resistant group of post-treatment samples. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Hallmark, KEGG and GOBP enrichment results for down-regulated genes in resistant group of post-treatment samples. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Top

Mechanism analysis of drug resistance-related DEGs for each cell type in one patient or cell lines

This dataset only has one patient or is a cell line dataset, the resistant sample is the post-treatment sample and the sensitive sample is the pre-treatment sample. Enrichment results for 5 known drug resistance mechanisms in malignant cells and 1 known mechanism in TME cells are shown here.The "Signature" column represents the differentially expressed genes (DEGs) used for enrichment. The "Geneset" column represents the genes included in this mechanism. The "Overlap" column represents the number of genes in the "Geneset" that are enriched in the "Signature". The "Enriched Genes" column represents the genes in the "Geneset" that are enriched in the "Signature". (If the image exists, the user can click on it to enlarge it in a new window.)

Enrichment results for 5 known drug resistance mechanisms in malignant cells

Mechnism	Pval	FDR	Signature	Geneset	Overlap	Background	Cell type	Enriched Genes
Unusual Activation of Pro-survival Pathway	3.90e-06	2.00e-05	1480	781	82	23467	Malignant cells	BAX,CDK4,CTNNB1,DNMT1,DUSP6,GSTP1,HMGA1,HMGA2,HMGB1,PKM,MAP1LC3B,NFKB1,PARP1,RHOA,S100A4,SHC1,ST3GAL4,SOX4,STMN1,SLC25A5,AKAP12,ALDH1A3,ATG3,BAD,BID,BRD4,CCND1,CD44,HSPD1,CLTC,CAPNS1,DDIT3,EIF3A,HSP90B1,ERCC1,FTL,FUS,GAPDH,NR3C1,HSPA8,HSPB1,EIF4A1,IL24,KDM5B,LDHA,MTDH,MAGEA3,NQO1,PGK1,AGPAT2,POMP,PRKDC,PSMB5,PSMG2,RAC1,RAP1B,ERBB3,RRM2,HNRNPA1,SDHB,SMC4,SRI,SOX10,SRSF2,STAT3,TGFA,TGFB2,TMED3,TMEM54,TOP1,UBE2C,YBX1,ENO1,MAGEA4,GNAS,CALR,NPM1,EIF4EBP1,PPP3CA,PMVK,TRIB3,BIRC2
Drug Inactivation by Structure Modification	2.40e-01	6.00e-01	1480	27	3	23467	Malignant cells	GSTP1,GSS,NME1
Irregularity in Drug Uptake and Drug Efflux	6.90e-01	1.00e+00	1480	37	2	23467	Malignant cells	SLC3A2,SLC7A5
Aberration of the Drug's Therapeutic Target	8.30e-01	1.00e+00	1480	90	4	23467	Malignant cells	CDK4,NPM1,COMT,TOP2A
Epigenetic Alteration of DNA, RNA or Protein	1.00e+00	1.00e+00	1480	455	13	23467	Malignant cells	DNMT1,EIF4G2,LMNA,TRIP6,PMAIP1,GAPDH,SMC4,TIMP1,MALAT1,GDI2,PPP1R15A,MT-CO2,NORAD

Hallmark, KEGG and GOBP enrichment results for up-regulated genes in resistant group. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Up-regulated Hallmark	Up-regulated KEGG	Up-regulated GO BP

Hallmark, KEGG and GOBP enrichment results for down-regulated genes in resistant group. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Down-regulated Hallmark	Down-regulated KEGG	Down-regulated GO BP

Top

MicroRNAs (miRNAs) regulating drug resistance-related DEGs for malignant cells

In the pre-treatment samples, the miRNAs with a score greater than 80 that regulate the top10 abs(avg_log2FC) drug resistance-related DEGs for malignant cells are shown here. If the gene does not have any miRNAs with a score greater than 80, it will not be shown. Here only the names of miRNAs with a score greater than 90 are shown, but some names will not be shown because of too many overlaps. (Complete files containing all datasets and cell types can be downloaded from the download section.)

In the post-treatment samples, the miRNAs with a score greater than 80 that regulate the top10 abs(avg_log2FC) drug resistance-related DEGs for Malignant cells are shown here. If the gene does not have any miRNAs with a score greater than 80, it will not be shown. Here only the names of miRNAs with a score greater than 90 are shown, but some names will not be shown because of too many overlaps. (Complete files containing all datasets and cell types can be downloaded from the download section.)

This dataset only has one patient or is a cell line dataset, the resistant sample is the post-treatment sample and the sensitive sample is the pre-treatment sample. The miRNAs with a score greater than 80 that regulate the top10 abs(avg_log2FC) drug resistance-related DEGs for Malignant cells are shown here. Here only the names of miRNAs with a score greater than 80 are shown, but some names will not be shown because of too many overlaps. If the gene does not have any miRNAs with a score greater than 90, it will not be shown. (Complete files containing all datasets and cell types can be downloaded from the download section.)

Regulating up-regulated DEGs in resistant group	Regulating down-regulated DEGs in resistant group

Top

Motifs and transcription factors (TFs) regulating drug resistance-related DEGs for each cell type

In the pre-treatment samples, the motifs and TFs that regulate drug resistance-related DEGs for each cell type are shown here. (Complete files can be downloaded from the download section.)

In the post-treatment samples, the motifs and TFs that regulate drug resistance-related DEGs for each cell type are shown here. (Complete files can be downloaded from the download section.)

This dataset only has one patient or is a cell line dataset, the resistant sample is the post-treatment sample and the sensitive sample is the pre-treatment sample. Motifs and TFs that regulate drug resistance-related DEGs for each cell type are shown here. (Complete files can be downloaded from the download section.)

Motifs and TFs regulating up-regulated DEGs in resistant group

motif	motif	NES	AUC	TF_highConf	Cell_type
	hdpi__TP73	5.09	0.0783	TP73 (directAnnotation).	Malignant cells
	metacluster_141.4	4.77	0.0751	GLIS2 (directAnnotation).	Malignant cells
	swissregulon__hs__ETV6	4.22	0.0695	ETV6 (directAnnotation).	Malignant cells
	hocomoco__TYY2_HUMAN.H11MO.0.D	4.11	0.0683	YY2 (directAnnotation).	Malignant cells
	transfac_pro__M06135	4.07	0.068	ZNF28 (directAnnotation).	Malignant cells
	metacluster_141.6	4.01	0.0673	MZF1; TAF1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY2; YY2; ZFP42; ZFP42; ZFP42; ZFP42; ZFP42; ZFP42; ZNF597 (directAnnotation). TAF1; TAF1L (inferredBy_Orthology).	Malignant cells
	flyfactorsurvey__pho_SOLEXA_F1-3	3.81	0.0653	YY1 (inferredBy_Orthology).	Malignant cells
	taipale_tf_pairs__ETV5_HOXA2_RSCGGWAATKR_CAP	3.54	0.0626	ETV5; HOXA2 (directAnnotation).	Malignant cells
	metacluster_155.3	3.47	0.0619	PLAG1 (directAnnotation). PLAG1 (inferredBy_Orthology).	Malignant cells
	taipale_tf_pairs__ELK1_TEF_NSCGGAWNTTACGTAAN_CAP	3.27	0.0598	ELK1; TEF (directAnnotation).	Malignant cells

Page: 1 2 3

Motifs and TFs regulating down-regulated DEGs in resistant group

motif	motif	NES	AUC	TF_highConf	Cell_type
	taipale_tf_pairs__ETS2_RCCGGAAGTG_HT	8.66	0.0737	ETS2 (directAnnotation).	Malignant cells
	transfac_pro__M04826	7.51	0.0667	EP300 (directAnnotation).	Malignant cells
	jaspar__MA1483.2	6.57	0.061	ELF2 (directAnnotation).	Malignant cells
	hdpi__FLI1	6.32	0.0595	FLI1 (directAnnotation).	Malignant cells
	metacluster_191.3	6.25	0.0591	EHF; ELF1; ELF1; ELF1; ELF4; ELK1; ELK3; ELK3; ELK4; ELK4; ERF; ETS1; ETS2; ETV3; ETV4; ETV5; FEV; FEV; FLI1; FLI1; GABPA; GABPA; GABPA; GABPA; GABPA; GABPA; SPDEF; ZNF200 (directAnnotation). ELK1; ELK1; ELK3; ELK3; ELK4; ELK4; ETV1; ETV1; ETV4; ETV4; ETV4; ETV5; GABPA; GABPA (inferredBy_Orthology).	Malignant cells
	metacluster_191.2	6.15	0.0584	ELK4; NR2C2; NR2C2; NR2C2; NR2C2 (directAnnotation). GABPA (inferredBy_Orthology).	Malignant cells
	metacluster_166.2	5.86	0.0567	ELK4; ETS1; ETS1; ETV1; ETV3; ETV4; ETV5; ETV7 (directAnnotation). GABPA (inferredBy_Orthology).	Malignant cells
	taipale_tf_pairs__ELF2_NATGCGGAAGTR_HT	5.76	0.0561	ELF2 (directAnnotation).	Malignant cells
	metacluster_166.4	5.73	0.0559	BCLAF1; EHF; ELF1; ELF1; ELF1; ELF1; ELF1; ELF1; ELF2; ELF2; ELF4; ELK1; ELK1; ELK1; ELK1; ELK1; ELK1; ELK1; ELK1; ELK1; ELK3; ELK3; ELK3; ELK3; ELK4; ERG; ERG; ERG; ERG; ETS1; ETS1; ETS1; ETS1; ETS1; ETV1; ETV1; ETV1; ETV1; ETV2; ETV3; ETV4; ETV4; ETV4; ETV4; ETV4; ETV5; ETV7; FEV; FEV; FLI1; FLI1; FLI1; FLI1; GABPA; GABPA; GABPA; GABPA; GABPA; GABPA; GABPB1; GATAD1; PHF20; ZBTB25; ZBTB40 (directAnnotation). EHF; ELF1; ELF1; ELF3; ELF5; ELK3; ELK4; ERG; ETS1; ETV1; ETV2; ETV4; FLI1; GABPA; GABPA (inferredBy_Orthology).	Malignant cells
	jaspar__MA1933.1	5.61	0.0551	SREBF2 (directAnnotation).	Malignant cells

Page: 1 2 3 4 5

Top

Differentially expressed genes act as transcription factors

This table shows the differentially expressed genes that act as transcription factors. (Complete files can be downloaded from the download section.)

TF	motif	Expression	Cell type	Timepoint
ETV4	metacluster_191.3	down	Malignant cells	NA
ETV4	metacluster_166.2	down	Malignant cells	NA
ETV4	metacluster_166.4	down	Malignant cells	NA
ETV4	taipale_tf_pairs__HOXB2_ETV4_ACCGGAAATGAN_CAP	down	Malignant cells	NA
ETV4	hdpi__ETV4	down	Malignant cells	NA
ETV4	taipale_tf_pairs__FOXO1_ETV4_RCCGGAWGTKKN_CAP	down	Malignant cells	NA
ETV4	metacluster_138.2	down	Malignant cells	NA
ETV4	taipale_tf_pairs__HOXB2_ETV4_ACCGGAAATGAN_CAP	down	Malignant cells	NA
ETV4	taipale_tf_pairs__GCM1_ETV4_RTGCGGGCGGAAGTR_CAP	down	Malignant cells	NA

Page: 1

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."